Our Global Capital Confidence Barometer shows that policy reform and portfolio rationalization have heightened dealmaking activity across the life sciences spectrum.
Life sciences dealmaking expected to continue
Australia’s diverted profits tax
Cracking the engaged aging code through technology
Global Corporate Divestment Study: Life sciences
It’s time to bring drug pricing down
The 2017 outlook for life sciences
SEC comments and trends: Life sciences
The drug pricing debate: Managing risks to results
Finding sustainability in biotechnology, pharmaceutical and medical technology
Amplified business decisions are the new norm thanks to rapid changes. From new market entrants and regulatory reform to expiring patents and the growing challenge of chronic diseases, leaders in the life sciences community must explore a new course to address the changing climate for health care — one driven by patients and focused on health outcomes.
Our Global Life Sciences Center brings together a worldwide team of professionals to help you achieve your potential.
We cover key issues in these areas:
Connect with us
Stay connected with us through social media, email alerts or webcasts. Or download our EY Insights app for mobile devices.
Have investor-friendly capital allocation and new competitors upended the world order in M&A? Find out how the biopharma sector is facing this challenge.